Article ID Journal Published Year Pages File Type
10962673 Vaccine 2016 6 Pages PDF
Abstract
We did not identify any new or unexpected safety concerns for PPSV23. The VAERS data are consistent with safety data from pre-licensure clinical trials and other post-licensure studies.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013
Authors
, , , , , ,